BioXcel Therapeutics (BTAI) PT Raised to $68 at Canaccord Genuity, More Upside Exists
Tweet Send to a Friend
Canaccord Genuity analyst Sumant Kulkarni raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $68.00 (from $27.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
